Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Accumulated Expenses for 10 consecutive years, with $83.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 33.83% to $83.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.9 million through Dec 2025, up 33.83% year-over-year, with the annual reading at $83.9 million for FY2025, 33.83% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $83.9 million at Rhythm Pharmaceuticals, down from $84.5 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $84.5 million in Q3 2025, with the low at $7.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $42.6 million, with a median of $40.0 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses plummeted 36.6% in 2021, then skyrocketed 252.43% in 2022.
  • Over 5 years, Accumulated Expenses stood at $30.1 million in 2021, then rose by 9.34% to $32.9 million in 2022, then surged by 46.72% to $48.3 million in 2023, then grew by 29.83% to $62.7 million in 2024, then soared by 33.83% to $83.9 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $83.9 million, $84.5 million, and $69.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.